Neuraxpharm

Neuraxpharm, a pharmaceutical preparation manufacturer headquartered in Spain, reported total carbon emissions of approximately 126,799,710 kg CO2e in 2025. This figure includes Scope 1 emissions of 2,162,030 kg CO2e, Scope 2 emissions of 1,790,610 kg CO2e, and Scope 3 emissions of 122,847,070 kg CO2e.

In the preceding years, Neuraxpharm's emissions were:

• 2024: Total emissions of about 119,136,260 kg CO2e, comprising Scope 1 at 2,052,450 kg CO2e, Scope 2 at 1,966,500 kg CO2e, and Scope 3 at 115,117,310 kg CO2e.
• 2023: Total emissions of approximately 117,214,390 kg CO2e, with Scope 1 at 1,655,640 kg CO2e, Scope 2 at 1,757,390 kg CO2e, and Scope 3 at 113,801,360 kg CO2e.
• 2022: Total emissions for Scope 1 and 2 were 3,526,000 kg CO2e, consisting of Scope 1 at 2,064,000 kg CO2e and Scope 2 at 1,462,000 kg CO2e. Scope 3 data was not disclosed for this year.
• 2021: Scope 1 emissions were 389,000 kg CO2e and Scope 2 emissions were 749,000 kg CO2e. No Scope 3 data was disclosed.
• 2020: Scope 1 emissions were 658,000 kg CO2e and Scope 2 emissions were 2,038,000 kg CO2e. No Scope 3 data was disclosed.

Neuraxpharm has not reported any specific public reduction targets, SBTi reduction targets, or a climate pledge at this time.